Skip to main content

Table 1 The baseline demographic characteristics of the patients with and without VSP during follow-up

From: High level of serum complement 3 is a risk factor for vascular stenosis progression in TA patients receiving tocilizumab: a prospective observational study

 

Total (n = 38)

Non-VSP (n = 20)

VSP (n = 18)

p-value

Age, years

27.3 ± 10.7

30.8 ± 11.8

23.6 ± 8.4

0.040

Gender (female), n (%)

35 (92.1)

19 (95.0)

16 (88.9)

0.595

Disease duration, months

12.9 (5.0–33.4)

16.9 (6.4–94.1)

9.0 (5.0–15.3)

0.151

VSP period, months

7.0 (5.8–10.8)

7.3 (6.0–12.6)

6.9 (5.6–9.2)

0.745

Naïve, n (%)

18 (47.3)

8 (40.0)

10 (55.6)

0.338

Refractory/severe, n (%)

9 (23.7)/29 (76.3)

4 (20.0)/16 (80.0)

5 (27.8)/13 (72.2)

0.709

Hypertension, n (%)

5 (13.2)

4 (20.0)

1 (5.6)

0.344

Vascular types, n (%)

   

0.389

 I

10 (26.3)

5 (25.0)

5 (27.8)

 

 IIa

4 (10.5)

2 (10.0)

2 (11.1)

 

 IIb

5 (13.2)

1 (5.0)

4 (22.2)

 

 V

19 (50)

12 (60.0)

7 (38.9)

 

Symptoms

 Fever, n (%)

4 (10.5)

2 (10)

2 (11.1)

1.000

 Amaurosis, n (%)

4 (10.5)

3 (15)

1 (5.6)

0.606

 Neck pain, n (%)

5 (13.2)

3 (15)

2 (11.1)

1.000

 Visual loss, n (%)

5 (13.2)

3 (15)

2 (11.1)

1.000

 Thoracalgia, n (%)

6 (15.8)

3 (15)

3 (16.7)

1.000

 Fatigue, n (%)

8 (21.1)

4 (20)

4 (22.2)

1.000

Signs

 Pulselessness, n (%)

11 (28.9)

5 (25)

6 (35.3)

0.495

 Vascular murmur, n (%)

13 (34.2)

3 (15)

10 (58.8)

0.008

Laboratory parameters

 Hemoglobin, g/L

112.3 ± 18.6

112.1 ± 23.0

112.6 ± 12.6

0.933

 WBC, × 109/L

8.9 ± 3.5

8.4 ± 3.8

9.5 ± 3.2

0.371

 Platelet, × 109/L

329.4 ± 108.9

294.4 ± 95.2

368.6 ± 112.4

0.039

 ALT, U/L

11.0 (8.0–19.0)

12.4 ± 6.7

15.6 ± 9.9

0.255

 Albumin, g/L

42.0 (39.0–43.0)

42.0 (39.0–46.0)

42.0 (40.3–43.0)

0.533

 Globin, g/L

29.29 ± 4.90

27.53 ± 4.48

31.38 ± 4.67

0.018

 Creatinine, μmol/L

54.0 (47.0–67.0)

72.2 ± 52.9

53.9 ± 14.9

0.190

 Blood urine nitrogen, μmol/L

4.8 ± 1.7

4.8 ± 1.8

4.7 ± 1.5

0.816

Inflammatory markers

 ESR, mm/h

44.8 ± 30.6

35.8 ± 26.1

54.9 ± 32.7

0.053

 CRP, g/L

12.4 (1.6–39.5)

17.3 ± 23.5

37.8 ± 41.7

0.069

 C3, g/L

1.20 ± 0.28

1.07 ± 0.19

1.34 ± 0.30

0.005

 C4, g/L

0.26 ± 0.08

0.25 (0.20–0.27)

0.27 (0.22–0.34)

0.240

 CH50, g/L

68.0 ± 21.5

61.8 ± 20.5

74.6 ± 21.2

0.100

 IgG, g/L

12.9 ± 3.3

12.4 ± 3.0

13.4 ± 3.6

0.382

 IL-6, pg/ml

9.3 (3.9–18.5)

7.2 (3.7–13.6)

14.4 (5.4–26.8)

0.156

 IL-8, pg/ml

7.3 (5.0–9.2)

7.0 (5.0–9.0)

8.0 (5.0–22.0)

0.493

 SAA, mg/L

30.4 (5.7–175.8)

9.1 (5.1–118.0)

104.8 (21.8–289.8)

0.023

 NIH score

3.0 (2.8–4.0)

3.0 (2.0–3.8)

3.0 (3.0–4.0)

0.105

Concomitant Immunosuppressants types, n (%)

   

0.194

 0

23 (60.5)

12 (60.0)

11 (61.1)

 

 1

12 (31.6)

5 (25.0)

7 (38.9)

 

 2

3 (7.9)

3 (15.0)

0

 
  1. The immunosuppressants include methotrexate (10 cases), LEF (3 cases), rapamycin (3 cases), thalidomide (1 case), azathioprine (1 case), and mycophenolate mofetil (1 case)
  2. Reference values: ESR, < 20 mm/h; CRP, < 3 mg/L; C3, 0.70–1.40 g/L; C4, 0.10–0.40 g/L; CH50, 50.0–100.0 g/L; IgG, 8.60–17.40 g/L; IgA, 1.00–4.20 g/L; IgE, < 200 IU/ml; IL-6, < 3.4 pg/ml; IL-8, < 62 pg/ml; SAA, 0–6.4 mg/L
  3. Abbreviations: VSP vascular stenosis progression during follow-up, WBC white blood cells, ALT alanine transaminase, BUN blood urine nitrogen, ESR erythrocyte sedimentation rate, CRP C-reactive protein, C3 complement 3, C4 complement 4, CH50 50% hemolytic complement, IgG immunoglobin G, IgA immunoglobin A, IgE immunoglobin E, IL-6 interleukin-6, IL-8 interleukin-8, SAA serum amyloid A, NIH score National Institutes of Health score
  4. Continuous variables are expressed as mean ± standard error or median (interquartile range, IQR) according to their normality
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us